GeneDx (WGS) Projected to Post Quarterly Earnings on Wednesday

GeneDx (NASDAQ:WGS - Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Wednesday, April 30th. Analysts expect the company to announce earnings of $0.11 per share and revenue of $79.90 million for the quarter. GeneDx has set its FY 2025 guidance at EPS.

GeneDx (NASDAQ:WGS - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The firm had revenue of $95.64 million for the quarter, compared to analysts' expectations of $82.24 million. On average, analysts expect GeneDx to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

GeneDx Price Performance

WGS opened at $96.89 on Wednesday. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The stock's 50 day simple moving average is $94.57 and its 200 day simple moving average is $80.67. The firm has a market cap of $2.72 billion, a price-to-earnings ratio of -49.43 and a beta of 1.93. GeneDx has a 1 year low of $10.18 and a 1 year high of $115.60.

Analyst Ratings Changes

Several research analysts recently commented on the stock. TD Cowen lifted their target price on shares of GeneDx from $75.00 to $118.00 and gave the stock a "buy" rating in a research note on Tuesday, January 7th. The Goldman Sachs Group upped their price objective on shares of GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a research note on Wednesday, February 19th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $72.33.

Insider Activity at GeneDx

In other news, CEO Katherine Stueland sold 1,657 shares of the stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $78.48, for a total value of $130,041.36. Following the completion of the transaction, the chief executive officer now owns 3,937 shares of the company's stock, valued at approximately $308,975.76. This represents a 29.62 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Kevin Feeley sold 402 shares of GeneDx stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $90.05, for a total value of $36,200.10. Following the sale, the chief financial officer now owns 5,044 shares in the company, valued at $454,212.20. This represents a 7.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 138,780 shares of company stock worth $12,907,437 over the last 90 days. 27.30% of the stock is owned by company insiders.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.